Nurix Therapeutics (NRIX) Current Assets (2019 - 2026)

Nurix Therapeutics (NRIX) has reported Current Assets for 8 consecutive years, with $456.5 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Current Assets fell 11.42% year-over-year to $456.5 million; the TTM figure through May 2026 stood at $456.5 million (down 11.42% YoY), while the FY2025 annual figure was $606.8 million, down 2.03% from the prior year.
• Current Assets declined to $456.5 million in Q2 2026 per NRIX's latest filing, from $554.4 million in the prior quarter.
• Across five years, Current Assets topped out at $619.4 million in Q4 2024 and bottomed at $251.0 million in Q1 2024.
• Historically, Current Assets has averaged $406.5 million across 5 years, with a median of $397.7 million in 2022.
• Annual changes were most pronounced in 2023 — Current Assets slipped 24.49% — and 2025, when it jumped 124.61%.
• Nurix Therapeutics' Current Assets stood at $318.4 million in 2022, then decreased by 7.21% to $295.5 million in 2023, then soared by 109.6% to $619.4 million in 2024, then slipped by 2.03% to $606.8 million in 2025, then declined by 24.77% to $456.5 million in 2026.
• Business Quant data shows NRIX's Current Assets at $456.5 million in Q2 2026, $554.4 million in Q1 2026, and $606.8 million in Q4 2025.